FDA approval for Wegovy pill (once-daily oral semaglutide 25 mg) to reduce excess body weight and maintain weight reduction long term and to reduce the risk of major adverse CV events Novo Nordisk Novo Nordisk announced that the FDA has approved the Wegovy pill (once-daily oral semaglutide 25 mg) to reduce excess body weight and maintain weight reduction long term and to reduce the risk of major adverse cardiovascular events
Clinical trials have shown that participants experienced an average body mass reduction of approximately 20.9% over a 72-week period, with 32% achieving a reduction of at least 25%
The 13 states where Medicaid covers GLP-1 drugs for obesity are California, Kansas, Minnesota, Wisconsin, Michigan, Mississippi, Pennsylvania, Virginia, North Carolina, Massachusetts, New Hampshire, Delaware and Rhode Island
Berberine alleviates liver fibrosis through inducing ferrous redox to activate ROS-mediated hepatic stellate cells ferroptosis